TransMedics Group, Inc. (TMDX): Bellevue Group AG reduced its stake -43K shares
Bellevue Group AG reduced its stake in TransMedics Group, Inc., per its Q2 2025 13F.
- 131K
- Shares reported · -43K vs prior quarter
- 0.39%
- Disclosed portfolio weight
- $17.5M
- Reported value
- Holdings as of
- Jun 30, 2025
- Filed
- Aug 14, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 4, 2025InsiderDirector sold ~$520K of TMDX shares in the open market
- Aug 6, 2025InsiderCEO purchased ~$997K of TMDX shares in the open market
- Aug 7, 2025Insider · 1 personInsiders: 2 purchases (~$985K)
What came next
- Oct 3, 2025Company filing · Form 8-K · Acquisition or saleCompleted buying or selling a business or assets“As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the “Company”) on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by the Company on September 22, 2023, a Current Report on Form 8-K filed by the Company on November 13, 2023, a Current Report on Form 8-K filed by the Company on December 19, 2023, a…”
- Oct 29, 2025Company filing · Form 8-K · ResultsReported its results
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for TransMedics Group, Inc.
For TransMedics Group, Inc., OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TMDX page.
How this filing works
Explore the data
Common questions
What does this filing report about TransMedics Group, Inc. (TMDX) stock?
Bellevue Group AG reduced its stake in TransMedics Group, Inc., per its Q2 2025 13F. Now 131K shares, $17.5M reported value, 0.39% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Jun 30, 2025. Filed: Aug 14, 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about TransMedics Group, Inc. recently?
For TransMedics Group, Inc., OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the TMDX page.
Does this mean TMDX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at TransMedics Group, Inc.
- SEC Form 4Nov 12, 2026
- SEC Form 4Nov 12, 2026
- SEC Form 144Nov 9, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its TMDX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
